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We read with interest the publication in CardioVascular
and Interventional Radiology on results from the random-
ized prospective Emmy trial [1]. The Emmy trial was de-
signed to compare uterine artery embolization (UAE) and
hysterectomy as a treatment for symptomatic ﬁbroids.
From the beginning in 1995 [2] the knowledge on UAE is
increasing and extensive. Most published data and
acknowledged information are based on large case series.
Nowadays UAE is no longer considered experimental and
has deﬁnitely found its place in the whole spectra of
treatment options for symptomatic uterine ﬁbroids. One of
the advantages of UAE is the signiﬁcantly earlier recovery
after the procedure compared to hysterectomy [3].
A structural comparison of individual pain experience
between UAE and hysterectomy has never been published
in a randomized trial before. Unfortunately, no conclusions
can be drawn from the publication by Hehenkamp et al.
with regard to pain experience in patients after UAE and
hysterectomy, since the study was not designed for this
purpose. Many participating centers performed only a few
UAEs, without a ﬁxed pain management protocol.
We feel that a ﬁxed and extensive pain management
protocol is crucial when performing UAE. At our center,
where we perform an average of 140 UAEs per year, a
dedicated pain management protocol is followed. In the
Emmy trial, several analgesic approaches have been men-
tioned such as epidural anesthesia, opiates, nonsteroidal
anti-inﬂammatory drugs (NSAIDs), paracetamol, and
combinations. All analgesics used before, during, and after
the procedure until discharge were recorded. Three subdi-
visions in terms of pain management could be extracted:
paracetamol and NSAIDs only, opiates and or NSAIDs,
and epidural anaesthesia. After discharge most patients
were on medication such as paracetamol and/or NSAIDs.
Pain after discharge was obviated and patient analgesic use
recorded during 6 weeks. As already expected, patients
from the hysterectomy arm had signiﬁcantly higher pain
scores during the ﬁrst 24 hours after treatment. Average
pain scores >5 during hospitalization occurred in 31% of
the UAE group versus 52% in the hysterectomy arm
(p = 0.012). The majority of patients in both groups needed
opiates during the ﬁrst 24 hours as the strongest analgesic
option. Consequently, these patients had higher pain
scores, except for three individuals in the UAE arm who
needed epidural anesthesia because of unbearable pain
despite the administration of opiates.
Many protocols have been described for UAE, varying
from standard epidural anaesthesia to patient-controlled
analgesia (PCA) in combination with NSAIDs and parac-
etamol [4]. Some authors even advocate performing UAE
under general anesthesia [5]. Interpatient variations occur
and pain experience as well as pain intensity is unpre-
dictable [6]. No correlations have been detected concerning
age, embolization technique, and embolization material
size and type (spherical or nonspherical particles), as well
as size and/or localization of uterine ﬁbroids, although a
clear and signiﬁcant relation was demonstrated between
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Even the effects and role of the psychological status of the
patient is difﬁcult to obviate. Hehenkamp et al. conclude
that a ﬁxed pain medication protocol cannot be recom-
mended based on their results. They, however, agree that a
substantial proportion of patients ends up with high aver-
age pain scores, indicating an insufﬁcient pain control.
In our opinion an adequate and extensive pain man-
agement protocol for UAE is extremely important, for not
only the periprocedural but also the postprocedural period.
At our facility we started performing UAE for symptomatic
uterine ﬁbroids in 1997. Initially, we encountered many
problems with peri- and postprocedural pain management.
Our protocol, consisting of 10 mg morphine hydrochloride
intramuscularly prior to the procedure and 10 mg morphine
hydrochloride four times daily postprocedural, in combi-
nation with dicloﬁnac, 100-mg suppository, as well as
paracetamol, 1000 mg, four times daily, was not adequate
to combat the sometimes extensive pain experienced by a
considerable amount of patients.
In close cooperation with the Department of Gynaecol-
ogy and Anaesthesiology we developed an exclusive pain
management protocol tailored to UAE (Table 1). This
regimen is based on the fact that proper pain management
starts prior to the procedure, and not after the ﬁrst pain
experienced by the patient during or just after the procedure
itself. At our facility the patient receives an intravenous (IV)
drip infusion in the left hand when admitted to the ward. A
urine bladder catheter is installed, and, although debateded
by many authors, 2 g kefsol is administered IV 1 hour prior
to the procedure. One hour prior to the scheduled UAE
procedure the patient is transported to the recovery room
and a PCA pump is connected to the IV line loaded with 100
mg dipidolor and set to a lockout time of 5 minutes. Bolus
injections are restricted to 2 mg. The patient is carefully
instructed on how to operate the pump in case of heavy pain.
Just before the procedure the patient is preloaded with a 2-
mg bolus injection. During the UAE procedure the patient is
carefully monitored by an attending radiographer observing
physiological status (pulse oximeter) as well as patient
behavior and pain sensations. In most cases the patient will
be encouraged by the attending radiographer to operate the
button of the PCA pump, resulting in a 2-mg bolus injec-
tion, especially when any change in pain level is noticed.
In other words, early prevention of pain is important.
After the UAE procedure the patient is transported back to
the recovery room and carefully monitored before returning
totheward.ThePCApumpisresetto1-mgbolusinjections.
In most cases additional diclophenac, 100-mg suppository,
and paracetamol, 1000-mg suppository, is needed to keep
the pain under control. Accompanying dizziness and nau-
siness can be treated with zofran, 4 mg IV. In case of
insufﬁcient response, 1.25 mg droperidol IV is the next step,
whichcanberepeatedasecondtime.Lastbutnotleast,5mg
dexamethasone IV may be helpful. When sufﬁciently sta-
bilized according to pain and nausea, the patient can return
to the ward. In most cases after one night of discomfort and
pain, PCA can be omitted and the patient mobilized. The
urinary bladder catheter is removed and the patient can be
discharged, after oral and written instructions.
We strongly believe in this aggressive pain management
approach where we try not only to treat the periprocedural
pain but also to anticipate any postembolization pain and
discomfort.
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